Zyversa therapeutics announces published data demonstrating that plasma levels of inflammasome asc show promise as biomarker of early cognitive changes in older adults

This data supports the potential of plasma asc levels as a biomarker for early stages of cognitive decline, based on elevated asc levels in older adults (>60 years) who were cognitively normal at baseline but demonstrated cognitive decline one year later (ni) compared to asc levels in those who: were cognitively normal at both baseline and 1 year later (nn), and were cognitively impaired at both baseline and one year later (ii) inflammasome-induced neuroinflammation has been associated with early stages of cognitive decline in dementia associated with alzheimer's and parkinson's diseases. excessive inflammasome activation leads to cell death (pyroptosis) and systemic release of cell contents, including asc that can be measured in the plasma.
ASC Ratings Summary
ASC Quant Ranking